PHAT RSI Chart
Last 7 days
10.9%
Last 30 days
7.8%
Last 90 days
13.7%
Trailing 12 Months
-18.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 682.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 08, 2024 | henderson molly | sold | -38,128 | 11.1 | -3,435 | cfo and cbo |
Mar 22, 2024 | curran terrie | sold | -153,513 | 9.11 | -16,851 | president and chief executive |
Jan 24, 2024 | takeda pharmaceutical co ltd | sold | -30,000,000 | 8.1 | -3,703,700 | - |
Jan 19, 2024 | henderson molly | sold | -48,900 | 7.7533 | -6,307 | cfo and cbo |
Nov 20, 2023 | henderson molly | sold | -15,402 | 7.2415 | -2,127 | cfo and cbo |
Nov 08, 2023 | parikh asit | bought | 19,500 | 7.8 | 2,500 | - |
Nov 07, 2023 | parikh asit | bought | 31,040 | 7.76 | 4,000 | - |
Nov 06, 2023 | parikh asit | bought | 8,040 | 8.04 | 1,000 | - |
Nov 01, 2023 | henderson molly | acquired | - | - | 22,500 | cfo and cbo |
Nov 01, 2023 | nabulsi azmi | acquired | - | - | 32,500 | chief operating officer |
Which funds bought or sold PHAT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.37 | 28,130 | 307,417 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -61.66 | -330,046 | 265,723 | -% |
May 15, 2024 | Octagon Capital Advisors LP | added | 810 | 4,375,600 | 4,832,100 | 0.58% |
May 15, 2024 | Saturn V Capital Management LP | added | 212 | 3,859,000 | 5,320,480 | 2.13% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 29.42 | 377,410 | 1,124,180 | -% |
May 15, 2024 | BARCLAYS PLC | reduced | -43.23 | -154,000 | 300,000 | -% |
May 15, 2024 | Checkpoint Capital L.P. | added | 23.85 | 1,445,870 | 4,727,610 | 3.16% |
May 15, 2024 | Frazier Life Sciences Management, L.P. | unchanged | - | 15,062,800 | 107,361,000 | 4.53% |
May 15, 2024 | Ghost Tree Capital, LLC | added | 25.9 | 1,633,450 | 5,150,700 | 1.43% |
May 15, 2024 | Virtus ETF Advisers LLC | reduced | -6.42 | 8,374 | 103,025 | 0.06% |
Unveiling Phathom Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Phathom Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Phathom Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 |
Revenue | - | 1,912 | - | - |
Cost Of Revenue | - | 426 | - | - |
Gross Profit | - | 1,486 | - | - |
Operating Expenses | 1.5% | 71,440 | 70,390 | 30,077 |
S&GA Expenses | 8.8% | 62,010 | 56,997 | 18,598 |
R&D Expenses | -29.6% | 9,430 | 13,394 | 11,479 |
Interest Expenses | 31.8% | 17,168 | 13,029 | 9,217 |
Net Income | -4.1% | -82,852 | -79,570 | -37,814 |
Net Income Margin | -22.3% | -361.63* | -295.59* | - |
Free Cashflow | -56.0% | -69,060 | -44,272 | -39,883 |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -13.9% | 356 | 414 | 237 | 265 | 144 | 165 | 202 | 214 | 149 | 189 | 228 | 215 | 246 | 295 | 231 | 252 | 264 | 257 | 80.00 | - |
Current Assets | -14.4% | 340 | 397 | 227 | 258 | 140 | 161 | 198 | 209 | 146 | 187 | 225 | 211 | 243 | 291 | 227 | 249 | 262 | 256 | 78.00 | 1.00 |
Cash Equivalents | -15.5% | 322 | 381 | 214 | 249 | 130 | 155 | 197 | 207 | 138 | 183 | 225 | 210 | 238 | 287 | 226 | 247 | 257 | 244 | 74.00 | 1.00 |
Inventory | 20.7% | 1.00 | 1.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -8.6% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | - |
Liabilities | 3.8% | 505 | 487 | 255 | 247 | 234 | 240 | 228 | 221 | 111 | 117 | 125 | 82.00 | 82.00 | 101 | 75.00 | 64.00 | 55.00 | 29.00 | 232 | - |
Current Liabilities | 12.1% | 43.00 | 39.00 | 24.00 | 22.00 | 14.00 | 26.00 | 23.00 | 21.00 | 11.00 | 19.00 | 28.00 | 40.00 | 41.00 | 56.00 | 28.00 | 13.00 | 5.00 | 4.00 | 207 | 2.00 |
Long Term Debt | 8.1% | 149 | 138 | 99.00 | 98.00 | 97.00 | 95.00 | 94.00 | 92.00 | 91.00 | 90.00 | 88.00 | 37.00 | 36.00 | 40.00 | 41.00 | 45.00 | 46.00 | 23.00 | 23.00 | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | 10.00 | 12.00 | 7.00 | 6.00 | 1.00 | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 138 | 99.00 | 98.00 | 97.00 | 95.00 | 94.00 | 92.00 | 91.00 | 90.00 | 88.00 | 37.00 | 36.00 | 40.00 | 41.00 | 45.00 | - | 23.00 | - | - |
Shareholder's Equity | -104.1% | -148 | -72.76 | - | 18.00 | -90.19 | -74.81 | - | - | 38.00 | 72.00 | 103 | 132 | 164 | 194 | 156 | 188 | 209 | 228 | - | - |
Retained Earnings | -8.9% | -1,011 | -928 | -849 | -805 | -764 | -727 | -672 | -620 | -570 | -529 | -493 | -456 | -420 | -385 | -331 | -297 | -276 | -256 | -158 | -1.29 |
Additional Paid-In Capital | 0.8% | 863 | 856 | 831 | 823 | 675 | 652 | 646 | 614 | 608 | 602 | 597 | 589 | 585 | 580 | 488 | 486 | 485 | 484 | 6.00 | 0.00 |
Shares Outstanding | 1.0% | 59.00 | 58.00 | 57.00 | 57.00 | 44.00 | 41.00 | 38.00 | 38.00 | 38.00 | 31.00 | 37.00 | 37.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 526 | - | - | - | 198 | - | - | - | 684 | - | - | - | 552 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -57.6% | -69,020 | -43,797 | -31,914 | -22,200 | -39,669 | -41,041 | -35,016 | -25,716 | -44,757 | -41,262 | -29,066 | -28,364 | -49,765 | -28,200 | -20,727 | -9,344 | -11,417 | -23,384 | -7,108 | -5,211 | -807 |
Share Based Compensation | -77.1% | 5,626 | 24,584 | 6,140 | 7,253 | 7,048 | 6,657 | 5,816 | 5,885 | 5,775 | 4,338 | 4,419 | 4,237 | 3,818 | 2,379 | 2,070 | 828 | 563 | - | - | - | - |
Cashflow From Investing | 91.6% | -40.00 | -475 | -939 | -6.00 | -214 | -412 | -134 | -428 | -67.00 | -100 | -14.00 | -45.00 | -169 | -124 | -183 | -57.00 | -676 | - | - | - | - |
Cashflow From Financing | -95.3% | 9,900 | 211,993 | 13.00 | 141,502 | 14,072 | - | 24,596 | - | - | 163 | 44,029 | 104 | 412 | 89,459 | - | - | 25,000 | 192,771 | -1,299 | - | - |
Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Gross Profit [Abstract] | ||
Product revenue, net | $ 1,912 | $ 0 |
Cost of revenue | 426 | 0 |
Gross profit | 1,486 | 0 |
Operating expenses: | ||
Research and development (includes related party amounts of $679 and $175, respectively) | 9,430 | 11,479 |
Selling, general and administrative (includes related party amounts of $20 and $3, respectively) | 62,010 | 18,598 |
Total operating expenses | 71,440 | 30,077 |
Loss from operations | (69,954) | (30,077) |
Other income (expense): | ||
Interest income | 4,313 | 1,460 |
Interest expense | (17,168) | (9,217) |
Other (expense) income, net | (43) | 20 |
Total other expense | (12,898) | (7,737) |
Net loss and comprehensive loss | $ (82,852) | $ (37,814) |
Net loss per share, basic | $ (1.42) | $ (0.89) |
Net loss per share, diluted | $ (1.42) | $ (0.89) |
Weighted-average shares of common stock outstanding, basic | 58,371,480 | 42,354,520 |
Weighted-average shares of common stock outstanding, diluted | 58,371,480 | 42,354,520 |
Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 322,229 | $ 381,393 |
Prepaid expenses and other current assets | 12,748 | 13,194 |
Accounts receivable, net | 3,879 | 1,637 |
Inventory | 1,458 | 1,208 |
Total current assets | 340,314 | 397,432 |
Property, plant and equipment, net | 1,962 | 2,146 |
Operating lease right-of-use assets | 1,264 | 1,475 |
Restricted cash | 2,867 | 2,863 |
Inventory, noncurrent | 8,400 | 8,234 |
Other long-term assets | 1,692 | 1,692 |
Total assets | 356,499 | 413,842 |
Current liabilities: | ||
Accounts payable (including related party amounts of $33 and $25, respectively) | 8,403 | 12,601 |
Accrued expenses (including related party amounts of $3,169 and $2,694, respectively) | 16,541 | 17,197 |
Accrued interest | 1,307 | 1,146 |
Operating lease liabilities, current | 730 | 726 |
Current portion of revenue interest financing liability | 16,478 | 7,111 |
Total current liabilities | 43,459 | 38,781 |
Long-term debt, net of discount | 149,023 | 137,842 |
Revenue interest financing liability | 302,528 | 299,816 |
Operating lease liabilities | 292 | 462 |
Other long-term liabilities | 9,700 | 9,700 |
Total liabilities | 505,002 | 486,601 |
Commitments and contingencies (Note 4) | ||
Stockholders' deficit: | ||
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.0001 par value; authorized shares - 400,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 58,524,101 and 57,970,044 at March 31, 2024 and December 31, 2023, respectively | 5 | 5 |
Treasury stock -19 shares at March 31, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 863,029 | 855,921 |
Accumulated deficit | (1,011,537) | (928,685) |
Total stockholders' deficit | (148,503) | (72,759) |
Total liabilities and stockholders' deficit | $ 356,499 | $ 413,842 |